Ozempic Face: What Imaging Studies Measured, and What Treats It

“Ozempic face” is the hollow, older look some people develop as they lose weight on a GLP-1 drug, and the one imaging study we could find measured about 7% of midface volume lost for every 10 kg of body weight, mostly from the fat pads just under the skin.^[1] It had 20 patients and no comparison group, so it shows the volume loss is real but cannot show that the drug does anything to the face beyond the weight loss itself. Treatments exist, though almost none has been tested in people taking these drugs.

What did the imaging study of Ozempic face measure?

Researchers at one academic medical center searched their records for patients who had a GLP-1 prescription and head or neck CT or MRI scans from both before and after it, then measured midface volume on those scans. Twenty patients qualified. Their median age was 54, they had taken the drug for an average of 321 days, and they had lost an average of 11.0 kg.^[1]

The superficial result is the informative one. Volume there fell across the middle half of patients and scaled with the weight lost. The deep compartment was too scattered to read: its range runs from a 20% loss to a 15% gain.^[1]

To put the slope in context, the average person on Wegovy 2.4 mg in the STEP 1 trial lost 15.3 kg.^[18] Applying 7% per 10 kg to that figure gives roughly 11% of midface volume. That is an extrapolation from 20 people to a different group, so treat it as a sense of scale. Individual results scatter widely around that average.

How much can 20 scans tell you?

The authors describe it as one of the first quantitative assessments, and it remains the anchor measurement. Its limits are specific:

• No comparison group. Nobody who lost the same weight by diet or surgery was scanned the same way, so the study cannot say whether the drug adds anything to the effect of weight loss.
• Scans ordered for other reasons. These patients had head and neck imaging for their medical care, so they may not resemble everyone taking the drug.
• Widely varying exposure. The 321-day average carries a standard deviation of 291 days, and the abstract does not separate results by drug.
• Volume is not appearance. The study measured fat compartments. It did not ask whether anyone looked older or minded the change.

The wider literature adds context without closing those gaps. A 2024 systematic review of facial change after massive weight loss, drawing on 14 reports across surgical and medical weight loss, found the greatest fat loss along the mid-cheek, laxity in the central neck, and a higher apparent age, and it asked for more volumetric studies.^[2] A 2026 review of 40 human studies listed older age, a long history of obesity, rapid loss, poor hydration and low protein intake as risk factors for worse skin outcomes, while calling for prospective studies to pin these down.^[6] Most of that evidence is observational or case-level.

Is Ozempic face caused by the drug or by the weight loss?

The evidence points to weight loss, though no one has directly tested the alternative. Facial aging has been documented after bariatric surgery, with no GLP-1 drug involved, and dermatologists writing on the subject framed the open question as whether this is a new side effect or a natural consequence of losing weight quickly.^[2][3] In the scan study, the loss scaled with kilograms lost, which is what a weight-driven effect would look like.^[1] The Wegovy, Zepbound and Ozempic labels do not list facial volume loss or sagging as an adverse reaction.^[15][16][17]

A 2026 dermatology review argues that fat is only part of it, pointing to the fat layer within the skin, changes in facial bone and the loss of muscle.^[4] Each of those is a proposed contributor, since none has been measured in GLP-1 users the way midface fat has. The muscle question has more data in the rest of the body, and muscle volume versus muscle function covers why a scan result does not settle it.

We found no randomized trial that compared facial volume between a GLP-1 drug and the same weight loss by another route, and no trial of whether slower dose escalation protects the face. Whether these drugs change how long Botox lasts is just as unmeasured. Public interest has run well ahead of that evidence: searches for the term climbed steadily from June 2022 to June 2025 and moved with searches for filler.^[7]

What treats Ozempic face, and how was each option tested?

A 2025 systematic review of the plastic surgery literature found 23 articles and said surgical and nonsurgical options exist, while noting that the studies carried biases.^[5] Sorting the options by who was actually studied gives a clearer picture.

The filler trial is the strongest study here, and it shows the product can restore midface volume in general. It does not show how long a result lasts in someone whose weight is still falling, since its abstract does not describe people on GLP-1 drugs.^[10] Treating a face that is still losing volume also means measuring any result against a moving baseline, which is why the timing question comes up throughout the literature.^[4][8]

Energy devices call for caution, because the problem being treated is lost fat and sustained heating may injure fat cells.^[9] A 2026 review that searched through August 2026 concluded it is unknown whether standard device settings are effective or safe in medication-related facial volume loss, and that no device has been shown to restore fat, skin and muscle support together in a prospective GLP-1 study.^[9] It labels its own suggestions as hypotheses and not as clinical recommendations.^[9] Separately, a review of microfocused ultrasound found few serious events in published studies, but FDA’s device-report database held 106 records in which fat loss, nerve symptoms and scarring were the most frequent complaints.^[14] Such reports are unverified and cannot give a rate.

Creams and supplements have less to offer here. No cosmetic peptide has been tested for facial volume, as peptides in skincare explains, and the split-face trial above graded skin appearance without measuring volume.^[12] For collagen peptides, a 2025 meta-analysis of 23 trials found no skin benefit in the trials without company funding.^[19]

Stopping the drug is the other option people consider. We found no study that rescanned faces after treatment ended, so whether volume returns is unknown, and the weight that tends to come back carries its own costs, as what happens when you stop a GLP-1 sets out.

What to ask before you pay for treatment

• Is my weight still changing? An expert consensus panel treats timing and sequencing as central decisions for people losing weight on medication.^[8] Ask how a plan would change if you lose another 10 kg.
• How will the result be measured? The same panel rated three-dimensional volume analysis as an effective objective measure, with photo scales and patient-reported scores as qualitative ones.^[8] Consistent before-and-after imaging protects you from judging by memory.
• Will this treatment remove any fat I still have? Ask this about any heat-based device, and ask for the evidence in people with lost facial volume specifically.^[9]
• What do you see as the goal? The panel named looking as if they had regained weight as a major fear among patients.^[8] Say so if that is yours.